Kura Oncology (NASDAQ:KURA) Insider Sells 31,487 Shares

Kura Oncology, Inc. (NASDAQ:KURA) insider Teresa Brophy Bair sold 31,487 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $12.63, for a total transaction of $397,680.81. Following the sale, the insider directly owned 195,444 shares in the company, valued at $2,468,457.72. This represents a 13.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kura Oncology Trading Up 1.5%

Shares of NASDAQ KURA traded up $0.18 during midday trading on Friday, reaching $11.89. 2,025,795 shares of the stock were exchanged, compared to its average volume of 1,613,393. The company has a market capitalization of $1.06 billion, a P/E ratio of -3.53 and a beta of 0.38. Kura Oncology, Inc. has a 52-week low of $7.36 and a 52-week high of $12.90. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12. The stock has a 50 day moving average price of $10.48 and a 200-day moving average price of $9.44.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The business had revenue of $20.87 million for the quarter, compared to the consensus estimate of $20.16 million. Equities research analysts expect that Kura Oncology, Inc. will post -3.23 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on KURA shares. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Citizens Jmp reiterated a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a research note on Monday, June 15th. Sanford C. Bernstein set a $24.00 target price on Kura Oncology in a research report on Monday, June 15th. Jefferies Financial Group set a $24.00 price target on Kura Oncology in a research note on Thursday, May 28th. Finally, CLSA set a $24.00 price target on Kura Oncology in a report on Thursday, June 4th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.62.

Hedge Funds Weigh In On Kura Oncology

Hedge funds have recently made changes to their positions in the stock. IFP Advisors Inc boosted its holdings in Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after acquiring an additional 1,284 shares during the last quarter. Allworth Financial LP increased its stake in Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after acquiring an additional 1,553 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Kura Oncology by 49.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock worth $60,000 after purchasing an additional 1,888 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Kura Oncology by 471.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after purchasing an additional 9,958 shares during the period. Finally, Brevan Howard Capital Management LP acquired a new position in shares of Kura Oncology in the 2nd quarter valued at about $80,000.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.